Headquartered in Boulder, CO·Fiscal year ends December·NASDAQ: EWTX·edgewisetx.com
About Edgewise Therapeutics
Edgewise Therapeutics is a clinical-stage cardiovascular biotechnology company. It develops oral small-molecule therapies intended to restore cardiac equilibrium, meaning the balance of contraction and relaxation across the cardiac cycle. The company draws on expertise in integrated muscle physiology and small molecule drug development.
Its pipeline centers on two programs:
- **EDG-7500:** an investigational, first-in-class cardiac sarcomere modulator that acts on the regulatory light chain. It is designed to slow early contraction velocity and improve impaired cardiac relaxation in obstructive and nonobstructive hypertrophic cardiomyopathy (HCM). It completed the Phase 2 CIRRUS-HCM trial, and a Phase 3 trial is expected to start by year-end 2026.
- **EDG-15400:** a selective cardiac sarcomere modulator being studied in the Phase 2 EQUINOX-HFpEF trial for heart failure with preserved ejection fraction.
In July 2026, Edgewise sold its sevasemten program and muscular dystrophy business to Servier for [USD:1396000000] in upfront cash plus potential escrow and milestone amounts. The sale made the company a pure-play cardiovascular developer with no approved products and no revenue to date. Updated
The sale of the sevasemten muscular dystrophy program to Servier booked a $1.35 billion gain, flipping a chronically loss-making biotech to GAAP profit. Operations still burned, and all of that cash now rides on cardiovascular: a Phase 3 HCM trial of EDG-7500 is due to start by year-end.
Recent insider buying has been highlighted by purchases by Warren Buffett, Jack Ma, Carlos Slim, and John Paulson. Biotechs tempted insiders, as did public offerings.
Edgewise Therapeutics is a clinical-stage cardiovascular biotechnology company. It develops oral small-molecule therapies intended to restore cardiac equilibrium, meaning the balance of contraction and relaxation across the cardiac cycle.
What is the EWTX stock price target?
The Wall Street consensus 12-month price target for EWTX is $55.42.